Vaccine Maitri

On 1 January 2021, the Drug Controller General of India, approved the emergency or conditional use of Covishield.

[9] On 2 January 2021, Covaxin India's first COVID-19 vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage.

[11] By mid-March 2021, India was also supplying vaccines on a commercial basis to countries including Canada,[12] the UK,[13] and Saudi Arabia.

[3] In May, when COVAX was already short 140 million doses,[16] the Serum Institute announced that it expected to maintain its suspension of vaccine deliveries to COVAX through the end of 2021[17] due to the second wave of COVID-19 in India[18] and the US ban on export of key raw materials.

[19] As of 21 February 2022, India had exported total 16,29,63,500 doses including 1,42,67,000 vaccine provided as grant, 10,71,48,000 as commercial, and 4,15,48,500 through COVAX to 96 nations.